Abstract
During the COVID-19 pandemic a number of jurisdictions in the United States began to regularly report levels of SARS-CoV-2 in wastewater for use as a proxy for SARS-CoV-2 incidence. Despite the promise of this approach for improving situational awareness, the degree to which viral levels in wastewater track with other outcome data has varied, and better evidence is needed to understand the situations in which wastewater surveillance tracks closely with traditional surveillance data. In this study, we quantified the relationship between wastewater data and traditional case-based surveillance data for multiple jurisdictions. To do so, we collated data on wastewater SARS-CoV-2 RNA levels and COVID-19 case reports from July 2020 to March 2023, and employed Bayesian hierarchical regression modeling to estimate the statistical relationship between wastewater data and reported cases, allowing for variation in this relationship across counties. We compared different model structural approaches and assessed how the strength of the estimated relationships varied between settings and over time. These analyses revealed a strong positive relationship between wastewater data and COVID-19 cases for the majority of locations, with a median correlation coefficient between observed and predicted cases of 0.904 (interquartile range 0.823 – 0.943). Across locations, the COVID-19 case rate associated with a given level of wastewater SARS-CoV-2 RNA concentration declined over the study period. Counties with higher population size and of higher levels of urbanicity had stronger concordance between wastewater data and COVID-19 cases. Ideally, use of wastewater data for decision-making should be based on an understanding of their local historical performance.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This project is supported by cooperative agreement NU38OT000297 from the Centers for Disease Control and Prevention (CDC) and the Council of State and Territorial Epidemiologists (CSTE), and SHEPheRD contract 200-2016-91779 from the CDC. This work does not necessarily represent the views of the CDC or CSTE.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Email Address: Fayette Klaassen [fklaassen{at}hsph.harvard.edu], Ted Cohen [theodore.cohen{at}yale.edu], Joshua A. Salomon [salomon1{at}stanford.edu], Nicolas A. Menzies [nmenzies{at}hsph.harvard.edu]
Data Availability
All data used in this study that are available online are described in the manuscript. Some data, however, cannot be shared as the authors do not have permission to do so.
